替吉奥联合I^(125)放射性粒子治疗老年非小细胞肺癌临床观察

Above 75 years old in non small cell lung cancer S-1 combined with I^(125) irradiation Clinical observation of the particle

目的探讨75岁以上老年NSCLC患者,CT导引下经皮穿刺植入I^(125)放射性粒子联合单药替吉奥治疗肺癌的近期疗效、可行性及安全性。方法针对25例75岁以上NSCLC患者,应用单药替吉奥联合I^(125)放射性粒子植入组织间放疗进行临床治疗,观察2~4个月CT扫描的病情变化。结果术后2月、4月、6月随访,25例有效率分别为84%,88%,88%;主要并发症为气胸、少量咯血、厌食、轻度呕吐、皮肤色素沉着、白血球下降。结论应用单药替吉奥联合I^(125)放射性粒子植入组织间放疗治疗75岁以上老年NSCLC安全、并发症轻、近期疗效确切,值得推广。

Objectives Discussion over the age of 75 elderly patients with NSCLC,CT guided by the recent curative effect,percutaneous implantation of I^125radioactive particles combined with single agent S-1 in the treatment of lung cancer is feasible and safe sex. Methods 25 cases of NSCLC patients over the age of 75,single drug application S-1 combined with I^125 radioactive particles implantation brachytherapy for clinical treatment,observation of 2 months to 4 months CT scanning condition changes. Results after operation,2,4,and 6 months follow-up,25 cases of effective rate were 84%,88% and 88%; the main complications were pneumothorax,a small amount of hemoptysis,anorexia,mild vomiting,skin pigmentation,decreased white blood cells. Conclusions The application of single agent S-1 combined with I^125 radioactive particles implantation brachytherapy for the treatment of aged more than 75 years NSCLC is safe,complications of light,the recent curative effect,is worth promoting.